Citeline Podcasts

Scrip senior writer Joseph Haas overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and what that may mean for pharma M&A during the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.

Joshua Sabari, MD Lung Cancer Specialist Answers Questions on Treating Patients with ES-SCLC

Maximizing The UK Medtech Opportunity In Times Of Change by Citeline

In this episode of Medtech Connect, Medtech Insight senior regulatory writer Eliza Slawther interviews MedTech Europe’s digital lead Alexander Olbrechts about the interplay between EU medical device laws with proposed horizontal regulations that impact digital devices, such as the AI Act, the Data Act and the European Health Data Space. The importance of international harmonized standards, particularly for cybersecurity, is also discussed

Quick Listen: Scrip's Five Must-Know Things:

https://scrip.pharmaintelligence.informa.com/SC148297/Quick-Listen-Scrips-Five-MustKnow-Things?utm_source=sfmc&utm_medium=email&utm_campaign=Scrip%20Weekly%20Email

In this episode, HBW Insight catches up with Bayer Consumer Health’s Daniella Foster. Foster leads on the company’s public affairs and sustainability work, and so updates us on Bayer’s progress towards its net zero goals and also its Nutrient Gap Initiative, which aims to expand access to vitamins and minerals for 50 million people in underserved communities by 2030. Foster explains the business model behind sustainability, and how the company is expanding access to self-care products in other ways, for example via Rx-to-OTC switch. We also dig a bit deeper into thorny sustainability issues like greenwashing and offsetting, with Foster offering sage advice to consumer health industry colleagues.

Quick Listen: Scrip's Five Must-Know Things

https://scrip.pharmaintelligence.informa.com/SC148258/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporters and editors discuss questions about Sarepta’s Duchenne muscular dystrophy gene therapy candidate (0:32), the US FDA’s efforts to simplify the COVID-19 vaccine schedule (13:15), and industry’s ideas for Medicare price negotiation system changes (24:18).

Read More In The Pink Sheet

CBER Director Marks’ Intervention On Sarepta Gene Therapy Filing Decision Appears To Backfire: https://pink.pharmaintelligence.informa.com/PS148055/CBER-Director-Marks-Intervention-On-Sarepta-Gene-Therapy-Filing-Decision-Appears-To-Backfire

If New COVID-19 Vaccine Recommendations Land In the United States, Do They Make Sound? https://pink.pharmaintelligence.informa.com/PS148080/If-New-COVID19-Vaccine-Recommendations-Land-In-the-United-States-Do-They-Make-Sound

PhRMA’s Opening Gambit: Limiting Medicare Price Setting To The IRA's Minimum Discount: https://pink.pharmaintelligence.informa.com/PS148072/PhRMAs-Opening-Gambit-Limiting-Medicare-Price-Setting-To-The-IRAs-Minimum-Discount

CNS analysts discuss neurodegenerative disorders - Parkinson’s and Alzheimer’s disease

Alzheimer’s Disease Forecast

https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/alzheimers-disease/forecast/article155358.ece

Alzheimer’s Disease Analysis Report

https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/alzheimers-disease/disease-analysis/article209751.ece

Parkinson’s Disease Analysis Report

https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/parkinsons-disease/disease-analysis/article218480.ece

Parkinson’s Disease Forecast

https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/parkinsons-disease/forecast/article138452.ece

Other platforms

Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

Huahui Health CSO Li Wenhui sits down with Scrip in the office to discuss many of the key issues such as, how he views antivirals development post-COVID? how the company’s hepatitis drugs differentiated from others? Given the current antivirals from Gilead among others, why Li believed that the antiviral development remains vital?